(Total Views: 594)
Posted On: 03/05/2021 8:43:06 PM
Post# of 155792
Quote:
CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab
We are all too close to this stock. Anyone not close to the stock would read this as EXCEEDINGLY GREAT POSITIVE NEWS!!!!
CytoDyn executives and their doctor friends need to get on the media IMMEDIATELY this weekend about these results!
(6)
(0)
